Caplin Point Laboratories Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/e445199zsfwdb91kpq71wdq9.pdf

Key Takeaways


U.S. Strategy: B2C Transition Without Abandoning B2B

Vivek Partheeban: "We need to be a little bit patient here, because as we aim to work predominantly outside of the big GPOs and IDNs, there will be some amount of slow progress in the beginning. But once we start establishing direct connections with the hospitals, with the clinicians, pharmacies, etc we feel that this is going to be very much more sustainable and where pricing can be firm, the forecast can be much firmer and we are much more in control of our destiny over there."

Latin America: Deepening the Moat

C.C. Paarthipan: "When you cater to the bottom of the pyramid, you can't afford costly drugs. If you can give a quality medicine at affordable cost, then your customer becomes your raving fan."

Pipeline & New Bets: The 3-5 Year Horizon


Financial Health: Cash, Margins and the Working Capital Story


China Risk & Supply Chain

C.C. Paarthipan: "Sometimes back one of the Western economists said China is the country which you can derisk but not decouple."

Capex & Project Timelines


Guidance & Commitments

CommitmentSpecificsTimeline
U.S. revenue targetUSD 10 crore revenueBy FY27, with flexibility to FY28
First ready-to-use injectable bag launchLaunchJanuary
Prefilled syringe exhibit batches6-7 productsIn coming weeks
Onco OSD free hospital for BE studiesHospital completion3-4 months [2-3]
CTD dossier format conversionEntire process completed6-9 months
API Vizag plant commercial productionCommence productionApril or May
Injectable oncology startCommence operationsApril or May
Caplin One Labs PAT positiveFirst full year of operationsCurrent fiscal
Committed capex projects (INR 700 crores)Complete everything2 years, maximum 2-3.5 years
Onco Labs yieldStart yielding business1-2 years
Investment fruit (CSL, Onco Labs)Returns materializeNext 3 years
Stabilization and evolution periodCurrent phaseNext 18-24 months
LatAm new initiatives focusConcentrate on committed projects firstNext 2 years

Key Metrics

MetricQ2 FY25
Revenue growth17.8% YoY
H1 FY25 revenue growth17.0%
Core business growth13%
Caplin Steriles operating revenue₹92.42 cr
Caplin Steriles PAT₹12.60 cr
Caplin Steriles EBITDA₹29.27 cr
Caplin Steriles gross margin63%
Consolidated gross margin55%, sustained
Consolidated EBITDA margin35%, sustained
Consolidated PAT margin25%, sustained
R&D expenditure4.5% to 5% of revenue
Cash balance₹1,039 cr as of September 30, 2024, up from ₹916 cr at end of March
Cash accrual (first 7 months)₹180 cr
Capex spent (first 7 months)₹56 cr
Employee expense increase26% YoY, including ₹2.8 cr ESOP amortization
Caplin Steriles H1 FY25 growth40% from H1 FY24 to H1 FY25
Caplin One Labs turnover contribution₹12 cr, commenced production March 2024
U.S. ANDAs completed25
U.S. revenue guidance$10 cr by FY27
Profit share with U.S. licensing partners50%
Committed project capex₹700 cr, to be deployed over 2 to 3.5 years
Inventory₹327 cr, 50% in Central American warehouses, 20% in transit
Transit time60 to 75 days, available for sale in 100 days
Cumulative CSL investment (last 8 years)₹720 cr
Cumulative Onco Labs investment₹150 cr